The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab

An emerging clinical need is represented by identifying reliable biomarkers able to discriminate between responders and non-responders among patients showing imaging progression during the administration of immune checkpoints inhibitors for advanced non-small cell lung cancer (NSCLC). In the present...

Full description

Bibliographic Details
Main Authors: Matteo Bauckneht, Carlo Genova, Giovanni Rossi, Erika Rijavec, Maria Giovanna Dal Bello, Giulia Ferrarazzo, Marco Tagliamento, Maria Isabella Donegani, Federica Biello, Silvia Chiola, Lodovica Zullo, Stefano Raffa, Francesco Lanfranchi, Giuseppe Cittadini, Cecilia Marini, Egesta Lopci, Gianmario Sambuceti, Francesco Grossi, Silvia Morbelli
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
NSCLC
immune checkpoint inhibitors
pseudoprogression
systemic inflammation index
positron emission tomography
fluorodeoxyglucose
Online Access:https://www.mdpi.com/2072-6694/13/13/3117

Internet

https://www.mdpi.com/2072-6694/13/13/3117

Similar Items